Title:Identification and Ranking of Clinical Compounds with Activity Against Log-phase Growing Uropathogenic Escherichia coli
VOLUME: 17 ISSUE: 2
Author(s):Hongxia Niu, Rebecca Yee, Peng Cui, Shuo Zhang, Lili Tian, Wanliang Shi, David Sullivan, Bingdong Zhu, Wenhong Zhang and Ying Zhang *
Affiliation:Lanzhou Center for Tuberculosis Research and Institute of Pathogenic Biology, School of Basic Medical Sciences, Lanzhou University, Lanzhou, Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, Key Laboratory of Medical Molecular Virology, Department of Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, Beijing Research Institute for Tuberculosis Control, Beijing, Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, Lanzhou Center for Tuberculosis Research and Institute of Pathogenic Biology, School of Basic Medical Sciences, Lanzhou University, Lanzhou, Key Laboratory of Medical Molecular Virology, Department of Infectious Diseases, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205
Keywords:Log-phase, uropathogenic Escherichia coli, UTIs, clinical compound library, urinary tract infection, colistin.
Abstract:
Background: Uropathogenic Escherichia coli (UPEC) is a major cause of Urinary
Tract Infections (UTIs). Due to increasing antibiotic-resistance among UPEC bacteria, new
treatment options for UTIs are urgently needed.
Objective: To identify new agents targeting growing bacteria that may be used for the treatment of
antibiotic-resistant UTIs.
Methods: We screened a clinical compound library consisting of 1,524 compounds using a high
throughput 96-well plate assay and ranked the activities of the selected agents according to their
MICs against the UPEC strain UTI89.
Results: We identified 33 antibiotics which were active against log-phase clinical UPEC strain
UTI89. Among the selected antibiotics, there were 12 fluoroquinolone antibiotics (tosufloxacin,
levofloxacin, sparfloxacin, clinafloxacin, pazufloxacin, gatifloxacin, enrofloxacin, lomefloxacin,
norfloxacin, fleroxacin, flumequine, ciprofloxacin), 15 beta-lactam or cephalosporin antibiotics
(cefmenoxime, cefotaxime, ceftizoxime, cefotiam, cefdinir, cefoperazone, cefpiramide,
cefamandole, cefixime, ceftibuten, cefmetazole, cephalosporin C, aztreonam, piperacillintazobactam,
mezlocillin), 3 tetracycline antibiotics (meclocycline, doxycycline, tetracycline), 2
membrane-acting agents (colistin and clofoctol), and 1 protein synthesis inhibitor (amikacin).
Among them, the top 7 hits were colistin, tosufloxacin, levofloxacin, sparfloxacin, clinafloxacin,
cefmenoxime and pazufloxacin, where clinafloxacin and pazufloxacin were the newly identified
agents active against UPEC strain UTI89. We validated the key results obtained with UTI89 on
two other UTI strains CFT073 and KTE181 and found that they all had comparable MICs for
fluoroquinolones while CFT073 and KTE181 were more susceptible to cephalosporin antibiotics
and tetracycline antibiotics but were less susceptible to colistin than UTI89.
Conclusion: Our findings provide possible effective drug candidates for the more effective
treatment of antibiotic-resistant UTIs.
